HENAN LINGRUI PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.09 CNY | -6.21% |
|
-1.41% | +46.64% |
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 45% by 2026.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- The firm trades with high earnings multiples: 20.74 times its 2024 earnings per share.
- The company appears highly valued given the size of its balance sheet.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +46.64% | 2.09B | - | ||
| +43.33% | 6.34B | B- | ||
| -16.78% | 4.51B | C+ | ||
| -6.93% | 3.29B | B- | ||
| +3.89% | 3.2B | C | ||
| -0.88% | 2.59B | - | D+ | |
| -5.34% | 1.76B | - | - | |
| +1.60% | 1.7B | - | - | |
| -7.31% | 1.62B | C- | ||
| +47.94% | 1.55B | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 600285 Stock
- Ratings Henan Lingrui Pharmaceutical Co., Ltd.